Intended Use of ACRODAT:
The ACRODAT® interactive web-based software application is a disease specific tool intended to assist endocrinologists in evaluating disease activity in patients with acromegaly.
By entering data on 5 key clinical outcome measures (IGF-I, tumour status, co-morbidities, symptoms and quality of life), ACRODAT® will assess whether the patient is adequately controlled, shows mild disease activity or shows significant disease activity based on the clinical opinion of endocrinologists specialized in acromegaly (having evaluated similar, hypothetical patient cases).
The use of ACRODAT® can be independent of any therapeutic intervention and can be utilized at any stage of the disease.
The tool also allows the patient to complete an online Quality of Life questionnaire as requested by the Physician. Physicians will be invited to access ACRODAT® via an email from Pfizer. They will create their own personal account using login credentials (password and email). Patients are invited by the physician to complete Quality of Life questionnaires by logging in to ACRODAT® via a unique 6 digit code.
ACRODAT® was developed to assist clinicians in taking a more holistic approach to patient management by including symptoms and Quality of Life assessments.
Systematic monitoring will help track changes in the patient’s status over time and may help facilitate better treatment decisions.
Other factors not considered in ACRODAT® may influence the overall disease activity status of the patient. Physicians must utilize their own knowledge and judgment when assessing the disease activity of their patients and making adjustments to their plan of treatment.